DocDollars

Intercept Pharma Europe Ltd.

Great Britain (UK) · Reporting entity ID 100001336927

Total reported 2019–2025
$9.94M
#490 of 2,960 reporting companies — 0% of all reported industry payments
$0 in general payments across 0 records, plus $9.94M in research funding across 1,252 records.

How it breaks down

Research funding $9,937,406

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Intercept Pharma Europe Ltd. reported $9.94M to US doctors and teaching hospitals from 2019 to 2025, ranking #490 of 2,960 reporting companies. 100% of that was research funding and 0% general payments such as consulting, speaking, food and travel. 0 general payment records and 1,252 research records were filed.

Common questions about Intercept Pharma Europe Ltd.

How much has Intercept Pharma Europe Ltd. paid US doctors?

Intercept Pharma Europe Ltd. reported $9,937,406 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $0 in general payments, $9,937,406 in research funding.

How does Intercept Pharma Europe Ltd. rank among drug and device companies?

It ranks #490 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Intercept Pharma Europe Ltd. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.